New chemo drug could mean fewer shots for kids with leukemia
NCT ID NCT01574274
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study compares two forms of the chemotherapy drug asparaginase in 240 children and teens with acute lymphoblastic leukemia or lymphoblastic lymphoma. One drug (Oncaspar) is given every 2 weeks, while the new drug (SC-PEG) is given every 3 weeks and may last longer in the blood. The study also looks at whether adjusting treatment based on minimal residual disease can improve cure rates, and whether giving antibiotics early can prevent serious infections.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Calaspargase pegol (SC-PEG) and Oncaspar (both forms of the chemotherapy drug asparaginase)
What this could lead to
If it works, this could lead to a more convenient dosing schedule (every 3 weeks instead of every 2 weeks) with similar safety and effectiveness for children with ALL or lymphoblastic lymphoma.
What could go wrong
This is a Phase 2 trial, so results are still early. The new drug may not prove as safe or effective as the standard, and the study also tests changes in therapy based on minimal residual disease, which is not yet proven to improve cure rates.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOBLASTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Centre Hospitalier U. de Quebec
Québec, Quebec, Canada
-
Children's Hospital Boston
Boston, Massachusetts, 02215, United States
-
Columbia University Medical Center, Morgan Stanley Children's Hospital of New York-Presbyterian
New York, New York, 10032, United States
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Hasbro Children's Hospital
Providence, Rhode Island, 02903, United States
-
Hospital Sainte Justine, University of Montreal
Montreal, Quebec, Canada
-
McMaster University
Hamilton, Ontario, Canada
-
Montefiore Medical Center
New York, New York, 10467, United States